- Q4 2023 Medivir AB Earnings Call TranscriptFeb 15, 2024kr2.97 (+3.31%)Earnings
- Medivir AB to Discuss the Updated Data in Advanced Hepatocellular Carcinoma Call TranscriptJan 23, 2024
- Q3 2023 Medivir AB Earnings Call TranscriptOct 27, 2023kr5.73 (-10.26%)Earnings
- Q2 2023 Medivir AB Earnings Call TranscriptAug 18, 2023kr6.06 (-1.29%)Earnings
- Q1 2023 Medivir AB Earnings Call TranscriptApr 27, 2023kr6.11Earnings
- Q4 2022 Medivir AB Earnings Call TranscriptFeb 15, 2023kr7.05 (-3.37%)Earnings
- Medivir AB at Redeye Fight Cancer Day (Virtual) TranscriptJan 19, 2023
- Q3 2022 Medivir AB Earnings Call TranscriptNov 03, 2022kr6.61 (+0.75%)Earnings
- Q2 2022 Medivir AB Earnings Call TranscriptAug 19, 2022kr6.67 (+3.83%)Earnings
- Q1 2022 Medivir AB Earnings Call TranscriptApr 28, 2022kr6.54 (+1.01%)Earnings
- Q4 2021 Medivir AB Earnings Call TranscriptFeb 15, 2022kr6.84 (+1.21%)Earnings
- Q3 2021 Medivir AB Earnings Call TranscriptNov 03, 2021kr7.66 (+1.85%)Earnings
- Medivir AB to Discuss Update on the Progress and Plans for the MIV-818 Program Call TranscriptSep 16, 2021
- Q2 2021 Medivir AB Earnings Call TranscriptAug 19, 2021kr8.47 (-4.26%)Earnings
- Q1 2021 Medivir AB Earnings Call TranscriptApr 28, 2021kr6.55 (+1.27%)Earnings
- Q4 2020 Medivir AB Earnings Call TranscriptFeb 26, 2021kr6.88 (+0.84%)Earnings
- Medivir AB to Discuss Exclusive Licensing Agreement with IGM Biosciences for Birinapant Call TranscriptJan 12, 2021
- Q3 2020 Medivir AB Earnings Call TranscriptNov 10, 2020kr9.15 (-0.73%)Earnings
- Q2 2020 Medivir AB Earnings Call TranscriptAug 20, 2020kr9.55 (+1.57%)Earnings
- Q1 2020 Medivir AB Earnings Call TranscriptMay 05, 2020kr10.05 (-4.96%)Earnings
- Medivir AB R&D Day TranscriptMar 02, 2020
- Q4 2019 Medivir AB Earnings Call TranscriptFeb 13, 2020kr9.74 (-0.14%)Earnings
- Q3 2019 Medivir AB Earnings Call TranscriptNov 27, 2019kr14.77 (+2.09%)Earnings
- Q2 2019 Medivir AB Earnings Call TranscriptAug 28, 2019kr16.15 (-1.64%)Earnings
- Medivir AB to Discuss the Development of Phase IA Study with MIV-818 Call TranscriptJun 13, 2019
- Q1 2019 Medivir AB Earnings Call TranscriptMay 03, 2019kr11.95 (+2.19%)Earnings
Q4 2023 Medivir AB Earnings Call Transcript
Thank you, and welcome, everyone, to the Q4 conference call for Medivir, and let's get right into it. We'll touch on three different sort of topics today in today's call.
First and foremost, we have made significant progress in quarter four of 2023. The fostrox + Lenvima study continues to progress very nicely with regards to patients staying on treatment. We are seeing improved benefit, and we had our first external data presented at ASCO GI Conference just after New Year's.
As we communicated in Q3, we have been focused on accelerating the fostrox development program towards initiating a pivotal Phase 2b with the aim of both gaining accelerated approval. We believe that the data and the clinical benefit we're seeing with the data is strong, and the unmet medical need in the second-line HCC population is significant as there are no approved treatments beyond or after current standard of care first line.
And we have also said with regards to acceleration activities taken strides with regards to CMC and also initiated our regulatory processes to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)